新辅助化疗在晚期卵巢癌治疗中的疗效及对卵巢血流参数的影响

Efficacy of neoadjuvant chemotherapy for advanced ovarian cancer and the effect on parameters of blood flow

目的探讨新辅助化疗在晚期卵巢癌治疗中的疗效及对卵巢血流参数的影响。方法选取2015年1月至2017年1月间西安高新医院收治的78例晚期卵巢癌患者,采用随机数表法分为观察组和对照组,每组39例。对照组患者采用肿瘤细胞减灭术和术后化疗方案,观察组患者采用术前新辅助化疗+对照组治疗方案,比较两组患者临床疗效和卵巢血流参数情况。结果治疗前,两组患者血流参数及血管参数比较,差异无统计学意义(P>0.05)。治疗后,两组患者血流参数和血管参数均得到改善,且观察组均优于对照组,差异均有统计学意义(均P<0.05)。观察组患者治疗有效率为82.1%,高于对照组的56.4%,差异有统计学意义(P<0.05)。观察组患者复发时间为(17.88±3.22)个月,对照组为(14.12±4.24)个月,差异有统计学意义(P<0.05)。观察组患者2年生存率高于对照组,差异有统计学意义(P<0.05)。两组患者1年生存率比较,差异无统计学意义(P>0.05)。结论新辅助化疗可改善晚期卵巢癌患者卵巢血流参数和临床疗效,应用推广价值高。

Objective To investigate the efficacy of neoadjuvant chemotherapy for advanced ovarian cancer and the effect on parameters of blood flow.Methods A total of 78 patients with advanced ovarian cancer admitted to Xi’an High-Tech Hospital from January 2015 to January 2017 were selected and randomly divided into an observation group and a control group with 39 patients in each group.The observation group received preoperative neoadjuvant chemotherapy plus cytoreductive surgery and postoperative chemotherapy and the control group only received cytoreductive surgery plus postoperative chemotherapy.The clinical efficacy and ovarian blood flow parameters were compared between the two groups.Results Before treatment,there was no significant difference in parameters of blood flow and vessels between the two groups(P>0.05).After the treatment,parameters of blood flow and vascular were improved in both groups with the observation group better than the control group(all P<0.05).The clinical efficacy was 821%in the observation group,which was significantly higher than 56.4% of the control group(P<0.05).The recurrence time was 17.88±3.22 months in the observation group,and 14.12±4.24 months in the control group(P<0.05).In terms of survival rate,the 2-year survival rate was significantly higher in the observation group than in the control group(P<0.05).There was no significant difference in 1-year survival rat between the two groups(P>0.05).Conclusion Neoadjuvant chemotherapy can improve parameters of blood flow and clinical efficacy in patients with advanced ovarian cancer.The value for application promotion is high.